Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
复制标题
DOI：
10.1016/j.cllc.2023.08.006
复制
发表时间：
2023-10-31
影响因子：
3.6
通讯作者：
Salgia，Ravi
中科院分区：
文献类型：
--
作者：
Fricke，Jeremy;Wang，Joshua;Salgia，Ravi
临床实践要点·选择性RET-TKI，即selpercatinib和pralsetinib对非小细胞肺癌患者RET融合有效。·乳糜性腹水(CA)是RET-TKI患者中一种极其罕见的不良反应，可能与疾病的进展混淆。·影像、穿刺术和液体甘油三酯水平在诊断CA中至关重要。·RET-TKI剂量减少、高蛋白低脂饮食和每月注射奥曲肽都是RET-TKI诱发CA的有效治疗选择。·RET-TKI治疗患者CA的机制尚不清楚。
Clinical Practice Points•The selective RET-TKIs, ie, selpercatinib and pralsetinib are effective against RET fusions in patients with NSCLC.•Chylous ascites (CA) is an extremely rare adverse toxicity seen in patients on RET-TKIs and may be confused with the progression of disease.•Imaging, paracentesis, and fluid triglyceride levels are crucial in diagnosing CA.•RET-TKI dose reduction, a high-protein low-fat diet, and monthly octreotide injections are all effective management options for patients with RET-TKI-induced CA.•The mechanism of CA in patients treated with RET-TKIs remains poorly understood.